The Weekly Roundup

January 20, 2017 | Pamela Youngberg Dickson

The NCPA annual survey served up some interesting, but by no means surprising, nuggets. Complaints about DIR fees ranked top on the list of issues that registered concern among pharmacists. Douglas Hoey, NCPA CEO cited other top priorities like “long-standing, PBM-generated challenges” of transparency and preferred pharmacy designations and their impact on independent pharmacists. The Eighth Circuit hasn’t provided much hope, either. It recently handed an appellate decision in Pharmaceutical Care Management Association v. Gerhart to PCMA, effectively describing the much-sought-after transparency pharmacy advocates are pushing as “interference” under ERISA (The Employee Retirement Income Security Act). It was not a good day for independent pharmacy.

Here are few other stories that might be of interest:

[Editor’s note:] Our inboxes are stuffed with newsletters and our coffee tables stacked with magazines and industry digests. I’m sure yours are, too. So we’ve decided to run a weekly sampling of interesting stories, issues coverage, and business ideas we come across each week. We hope you’ll share some of your favorites, too. Drop us a line at solutions@smart-fill.com.

DIRFDALTCOpioid AbusPackagingPBMVaccine

Pamela Youngberg Dickson

Before she came to Smart-Fill, Pamela developed marketing strategy and content for a range of technology start-ups and large-cap enterprises. Outside the office, she's into gardening, renaissance history, the Big Ten, and exploring the great outdoors.